🔴 Compass Pathways is trading 5.2% down today amid biotech weakness and broader risk-off sentiment

Compass Pathways is trading at $12.94 (down 5.2%) as the biotech sector faces pressure from broader risk-off market sentiment.

• No new company-specific news or analyst rating changes have been reported since the company's strong Phase 3 data and Q1 2026 results earlier this quarter.
• The current downward movement appears to be driven by macro and sector-wide trends rather than a fresh company-specific catalyst.